Stevanato Group S.p.A.
$15.86
▼
-0.15%
2026-04-21 09:39:02
www.stevanatogroup.com
NYQ: STVN
Explore Stevanato Group S.p.A. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.33 B
Current Price
$15.86
52W High / Low
$28 / $12.89
Stock P/E
26.32
Book Value
$6.28
Dividend Yield
0.39%
ROCE
9.9%
ROE
9.67%
Face Value
—
EPS
$0.59
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
6,010
Beta
0.62
Debt / Equity
31.6
Current Ratio
1.76
Quick Ratio
1.26
Forward P/E
15.82
Price / Sales
3.11
Enterprise Value
$4.03 B
EV / EBITDA
14.21
EV / Revenue
3.4
Rating
Buy
Target Price
$24.72
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Meaningful dividend yield is available.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Milestone Scientific Inc. | $0.29 | — | $23.33 M | — | -155% | -1.32% | $1.11 / $0.22 | $0.04 |
| 2. | Nyxoah SA | $3.23 | — | $121.16 M | — | -119.32% | -1.11% | $8.87 / $2.35 | $1.33 |
| 3. | ICU Medical, Inc. | $130.58 | 4,461.76 | $3.27 B | — | 3.08% | 0.04% | $160.29 / $107 | $86.03 |
| 4. | KORU Medical Systems, Inc. | $4.26 | — | $200.78 M | — | -14.86% | -15.58% | $6.61 / $2.08 | $0.37 |
| 5. | STAAR Surgical Company | $25.53 | — | $1.27 B | — | -11.99% | -21.7% | $30.81 / $15.59 | $6.97 |
| 6. | Repligen Corporation | $130.14 | 150.55 | $7.4 B | — | 1.48% | 2.4% | $175.77 / $109.66 | $37.39 |
| 7. | Anbio Biotechnology | $26.98 | 380.56 | $3.88 B | — | 11.61% | 27.05% | $55.65 / $6.05 | $0.63 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 346.48 M | 303.17 M | 280 M | 256.6 M | 330.64 M | — |
| Operating Profit | 70.08 M | 52.72 M | 41.4 M | 34.63 M | 66.84 M | — |
| Net Profit | 47.55 M | 36.06 M | 29.7 M | 26.52 M | 48.38 M | — |
| EPS in Rs | 0.96 | 0.73 | 0.6 | 0.53 | 0.97 | 0.11 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.19 B | 1.1 B | 1.09 B | 983.68 M |
| Operating Profit | 198.8 M | 161.14 M | 200.72 M | 192.43 M |
| Net Profit | 139.84 M | 117.78 M | 145.63 M | 142.85 M |
| EPS in Rs | 2.81 | 2.37 | 2.93 | 2.87 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.54 B | 2.33 B | 2.07 B | 1.66 B |
| Total Liabilities | 1.06 B | 924.43 M | 938.93 M | 663.79 M |
| Equity | 1.49 B | 1.4 B | 1.13 B | 996.13 M |
| Current Assets | 943.35 M | 880.12 M | 861.89 M | 845.77 M |
| Current Liabilities | 535.88 M | 477.47 M | 574.39 M | 462.5 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 286.08 M | 155.78 M | 105.21 M | 103.31 M |
| Investing CF | -272.92 M | -310.21 M | -421.22 M | -242.95 M |
| Financing CF | 22.06 M | 183.22 M | 158.03 M | -44.54 M |
| Free CF | 11.04 M | -157.79 M | -336.72 M | -139.81 M |
| Capex | -275.03 M | -313.57 M | -441.93 M | -243.13 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 1.72% | 10.34% | — | — |
| Earnings Growth % | -19.13% | 1.95% | — | — |
| Profit Margin % | 10.67% | 13.42% | 14.52% | — |
| Operating Margin % | 14.6% | 18.49% | 19.56% | — |
| Gross Margin % | 27.38% | 31.32% | 32.51% | — |
| EBITDA Margin % | 22.45% | 25.09% | 26.07% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2025-06-05 | $0.062 |
| 2024-06-04 | $0.058 |
| 2023-06-07 | $0.058 |
| 2022-06-13 | $0.054 |
Stock Splits
No stock split history available.